Argenica Therapeutics Limited researches and develops a neuroprotective therapeutic drug in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.38|
|52 Week High||AU$0.18|
|52 Week Low||AU$0.45|
|1 Month Change||-3.80%|
|3 Month Change||85.37%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||46.15%|
Recent News & Updates
We're Not Very Worried About Argenica Therapeutics' (ASX:AGN) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|AGN||AU Pharmaceuticals||AU Market|
Return vs Industry: Insufficient data to determine how AGN performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how AGN performed against the Australian Market.
Stable Share Price: AGN is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 11% a week.
Volatility Over Time: Insufficient data to determine AGN's volatility change over the past year.
About the Company
Argenica Therapeutics Limited researches and develops a neuroprotective therapeutic drug in Australia. The company’s product is ARG-007, a neuroprotective peptide candidate for use in the protection of brain tissue against damage during a stroke and other acute central nervous system injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Argenica Therapeutics Fundamentals Summary
|AGN fundamental statistics|
Is AGN overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|AGN income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.014|
|Net Profit Margin||-347.72%|
How did AGN perform over the long term?See historical performance and comparison
Is Argenica Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate AGN's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: AGN is unprofitable, so we can't compare its PE Ratio to the Oceanic Pharmaceuticals industry average.
PE vs Market: AGN is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate AGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: AGN is overvalued based on its PB Ratio (4.1x) compared to the AU Pharmaceuticals industry average (3.5x).
How is Argenica Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Argenica Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Argenica Therapeutics performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: AGN is currently unprofitable.
Growing Profit Margin: AGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if AGN's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare AGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AGN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.4%).
Return on Equity
High ROE: AGN has a negative Return on Equity (-15.04%), as it is currently unprofitable.
How is Argenica Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: AGN's short term assets (A$7.3M) exceed its short term liabilities (A$425.7K).
Long Term Liabilities: AGN has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: AGN is debt free.
Reducing Debt: AGN has not had any debt for past 5 years.
Debt Coverage: AGN has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: AGN has no debt, therefore coverage of interest payments is not a concern.
What is Argenica Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate AGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate AGN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if AGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if AGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of AGN's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Dr. Liz Dallimore (B. Sc. (Hons), MBA, PhD) is Chief Executive Officer of Argenica Therapeutics Limited. She is a research & development, innovation and commercialisation specialist with experience across...
CEO Compensation Analysis
Compensation vs Market: Liz's total compensation ($USD108.07K) is below average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: Insufficient data to compare Liz's compensation with company performance.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: AGN only recently listed within the past 12 months.
Argenica Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Argenica Therapeutics Limited
- Ticker: AGN
- Exchange: ASX
- Founded: 2019
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$27.805m
- Shares outstanding: 73.17m
- Website: https://argenica.com.au
- Argenica Therapeutics Limited
- 117 Broadway
- Unit 4
- Western Australia
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:36|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.